BR112021023274A2 - Formulações de terlipressina - Google Patents
Formulações de terlipressinaInfo
- Publication number
- BR112021023274A2 BR112021023274A2 BR112021023274A BR112021023274A BR112021023274A2 BR 112021023274 A2 BR112021023274 A2 BR 112021023274A2 BR 112021023274 A BR112021023274 A BR 112021023274A BR 112021023274 A BR112021023274 A BR 112021023274A BR 112021023274 A2 BR112021023274 A2 BR 112021023274A2
- Authority
- BR
- Brazil
- Prior art keywords
- terlipressin
- formulations
- terlipressin formulations
- pharmaceutical compositions
- disclosure provides
- Prior art date
Links
- 108010010056 Terlipressin Proteins 0.000 title abstract 3
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 title abstract 3
- 229960003813 terlipressin Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000007774 longterm Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851366P | 2019-05-22 | 2019-05-22 | |
| PCT/US2020/034269 WO2020237170A1 (en) | 2019-05-22 | 2020-05-22 | Formulations of terlipressin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023274A2 true BR112021023274A2 (pt) | 2022-03-08 |
Family
ID=73458147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023274A BR112021023274A2 (pt) | 2019-05-22 | 2020-05-22 | Formulações de terlipressina |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12156898B2 (enExample) |
| EP (1) | EP3972628A4 (enExample) |
| JP (1) | JP7579811B2 (enExample) |
| KR (1) | KR20220011697A (enExample) |
| CN (1) | CN114096267B (enExample) |
| AU (1) | AU2020279395B2 (enExample) |
| BR (1) | BR112021023274A2 (enExample) |
| CA (1) | CA3141488A1 (enExample) |
| CL (1) | CL2021003065A1 (enExample) |
| MX (1) | MX2021014310A (enExample) |
| WO (1) | WO2020237170A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020013389A (es) | 2018-06-15 | 2021-03-31 | Ferring Bv | Composiciones de terlipresina y usos de las mismas. |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
| CN115856149B (zh) * | 2022-12-26 | 2023-12-05 | 哈尔滨吉象隆生物技术有限公司 | 一种特利加压素中杂质的检测方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| US20040153032A1 (en) * | 2002-04-23 | 2004-08-05 | Garribotto John T. | Dispenser for patient infusion device |
| US6991800B2 (en) | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| US20040022792A1 (en) * | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| BRPI0406668A (pt) * | 2003-01-09 | 2005-12-20 | Baxter Healthcare Sa | Recipiente de segurança, processo para a produção do mesmo, e, uso de um meio que contém pelo menos um polìmero |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| DK1984012T3 (en) | 2006-02-13 | 2016-03-29 | Ferring Bv | USE OF peptidic vasopressin receptor agonists |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| US20100311655A1 (en) | 2007-06-07 | 2010-12-09 | Mdrna, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US9050286B2 (en) | 2007-08-14 | 2015-06-09 | Ferring B.V. | Use of peptidic vasopression receptor agonists |
| US20100311642A1 (en) | 2007-09-28 | 2010-12-09 | Ferring B.V. | Use of v2 receptor antagonists in combination with vaso pressinergic agnosts |
| WO2009062174A1 (en) | 2007-11-08 | 2009-05-14 | University Of Utah Research Foundation | Use of angiogenesis antagonists in conditions of abnormal venous proliferation |
| KR20210049186A (ko) | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8815232B2 (en) | 2008-08-26 | 2014-08-26 | Kyon Biotech Ag | Compositions and methods for treating cancer |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| EP2346901A1 (en) | 2008-10-20 | 2011-07-27 | Abbott Laboratories | Antibodies that bind to il-18 and methods of purifying the same |
| US20100203014A1 (en) | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
| US20100260739A1 (en) | 2009-03-09 | 2010-10-14 | Bioatla, Llc | Mirac Proteins |
| EP2440200B8 (en) | 2009-06-08 | 2014-10-15 | UCL Business PLC | Treatment of portal hypertension using l-ornithine phenylacetate |
| EP2446552B1 (en) * | 2009-06-24 | 2016-08-10 | Nokia Solutions and Networks Oy | Relay node and method for changing the timeslot type according to the received information |
| US8613892B2 (en) * | 2009-06-30 | 2013-12-24 | Abbott Diabetes Care Inc. | Analyte meter with a moveable head and methods of using the same |
| AU2011279144A1 (en) | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
| JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| CN102440957B (zh) * | 2011-12-16 | 2013-09-25 | 深圳市健元医药科技有限公司 | 醋酸特利加压素鼻腔喷雾剂及其制备方法 |
| WO2013106072A1 (en) | 2012-01-10 | 2013-07-18 | Sorbent Therapeutics, Inc. | Compositions comprising crosslinked cation-binding polymers and uses thereof |
| JO3109B1 (ar) | 2012-05-10 | 2017-09-20 | Ferring Bv | منبهات لمستقبلات v1a |
| CA2891281C (en) | 2012-11-12 | 2023-11-28 | The Regents Of The University Of Colorado, A Body Corporate | Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis |
| AU2014256944B2 (en) | 2013-04-26 | 2019-06-27 | La Jolla Pharma, Llc | Compositions and methods for treating renal failure |
| US20150056194A1 (en) | 2013-08-21 | 2015-02-26 | Georgia Regents Research Institute, Inc. | Modified green tea polyphenols and methods thereof for treating liver disease |
| US20150328317A1 (en) | 2014-05-13 | 2015-11-19 | Eagle Pharmaceuticals, Inc. | Aqueous buffer-free bivalirudin compositions |
| US20200237856A1 (en) | 2014-10-24 | 2020-07-30 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US20200046798A1 (en) | 2014-10-24 | 2020-02-13 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| CN107206049B (zh) | 2014-10-24 | 2021-12-07 | 马林克罗特医疗产品知识产权公司 | 治疗患1型肝肾综合征的患者的方法 |
| WO2017150824A1 (ko) | 2016-03-03 | 2017-09-08 | 가천대학교 산학협력단 | 마이크로 니들 및 이의 제조방법 |
| US20190249173A1 (en) * | 2016-05-04 | 2019-08-15 | Chandra Vargeese | Methods and compositions of biologically active agents |
| GB201721846D0 (en) | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| US11318183B2 (en) * | 2018-03-20 | 2022-05-03 | Mankind Pharma Ltd. | Stable pharmaceutical composition of vasopressin |
| MX2020013389A (es) | 2018-06-15 | 2021-03-31 | Ferring Bv | Composiciones de terlipresina y usos de las mismas. |
| CN108659104B (zh) * | 2018-07-03 | 2020-06-09 | 北京市新里程医药科技有限公司 | 一种特利加压素的制备方法及其药物组合物 |
| CN109010795B (zh) * | 2018-09-12 | 2021-10-22 | 南京康舟医药科技有限公司 | 醋酸特利加压素注射液以及其制备方法 |
| WO2020128499A1 (en) * | 2018-12-21 | 2020-06-25 | Arecor Limited | Novel composition |
-
2020
- 2020-05-22 KR KR1020217041832A patent/KR20220011697A/ko active Pending
- 2020-05-22 WO PCT/US2020/034269 patent/WO2020237170A1/en not_active Ceased
- 2020-05-22 BR BR112021023274A patent/BR112021023274A2/pt active Search and Examination
- 2020-05-22 JP JP2021569344A patent/JP7579811B2/ja active Active
- 2020-05-22 CN CN202080050758.XA patent/CN114096267B/zh active Active
- 2020-05-22 MX MX2021014310A patent/MX2021014310A/es unknown
- 2020-05-22 EP EP20809710.5A patent/EP3972628A4/en active Pending
- 2020-05-22 US US17/611,478 patent/US12156898B2/en active Active
- 2020-05-22 AU AU2020279395A patent/AU2020279395B2/en active Active
- 2020-05-22 CA CA3141488A patent/CA3141488A1/en active Pending
-
2021
- 2021-11-19 CL CL2021003065A patent/CL2021003065A1/es unknown
-
2022
- 2022-03-18 US US17/699,019 patent/US20220202907A1/en not_active Abandoned
-
2024
- 2024-11-15 US US18/949,355 patent/US20250249066A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114096267A (zh) | 2022-02-25 |
| WO2020237170A1 (en) | 2020-11-26 |
| CN114096267B (zh) | 2025-03-18 |
| MX2021014310A (es) | 2022-01-26 |
| CL2021003065A1 (es) | 2023-01-06 |
| JP7579811B2 (ja) | 2024-11-08 |
| US20250249066A1 (en) | 2025-08-07 |
| AU2020279395A1 (en) | 2021-12-16 |
| CA3141488A1 (en) | 2020-11-26 |
| JP2022533759A (ja) | 2022-07-25 |
| US20220233634A1 (en) | 2022-07-28 |
| EP3972628A1 (en) | 2022-03-30 |
| AU2020279395B2 (en) | 2025-08-28 |
| US20220202907A1 (en) | 2022-06-30 |
| EP3972628A4 (en) | 2023-01-18 |
| KR20220011697A (ko) | 2022-01-28 |
| US12156898B2 (en) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| EP3765522A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES | |
| EP3972584A4 (en) | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | |
| DK4328309T3 (da) | Lipidsammensætning | |
| EP4072520C0 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING CABOTEGRAVIR | |
| CL2021002592A1 (es) | Composiciones fungicidas. | |
| EP3749372C0 (en) | IL-12 COMPOSITIONS FOR TARGETING EDB | |
| BR112018002983A2 (pt) | composição compreendendo uma lactama e um álcool | |
| SI3927315T1 (sl) | Okusne formulacije | |
| SI3820446T1 (sl) | Farmacevtski sestavki, ki vsebujejo RPL554 v HFA-134A za uporabo z vdihavanjem | |
| EP4023292A4 (en) | Injection formulation | |
| IL292766A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| EP3986415A4 (en) | IBOGAIN FORMULATIONS | |
| EP3947466A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
| EA201791716A1 (ru) | Фармацевтический состав | |
| CL2021003065A1 (es) | Formulaciones de terlipressina | |
| MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
| EP4020945A4 (en) | DISPLAY TERMINAL | |
| LT4027973T (lt) | Vaistų tiekimo kompozicijos | |
| EP3977855A4 (en) | Stable microbicide composition | |
| EP3899996A4 (en) | ELECTROLYTE COMPOSITIONS | |
| DK3911298T3 (da) | Formuleringer | |
| JP2019181899A5 (enExample) | ||
| IL285005A (en) | Compositions comprising thymoquinone and additional biologically active compounds | |
| EP4038129A4 (en) | INSECT REPELLENT COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: VIDE PARECER |
|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: VIDE PARECER |
|
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.7 NA RPI NO 2763 DE 19/12/2023 POR TER SIDO INDEVIDA. |